The Board of Directors in their meeting held today i.e., on Friday, May 30, 2025 has approved the Audited standalone financial results and statements for the Fourth quarter and financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hindustan Bio Sciences Ltd reported audited FY25 results with revenue from operations falling about 22% to Rs 81.33 lakhs from Rs 103.90 lakhs in FY24. Despite the revenue decline, profit after tax jumped roughly 75% to Rs 10.08 lakhs (vs Rs 5.76 lakhs last year), helped by lower purchase and employee costs. Q4 alone swung to a profit of Rs 10.79 lakhs from a Rs 4.14 lakh loss in Q4 FY24. The auditor issued an unmodified opinion and confirmed there is no material uncertainty on the company's ability to continue as a going concern. The board also re-appointed the internal auditor for FY26 and proposed a new secretarial auditor for a five-year term. Long-term borrowings stood at Rs 250.51 lakhs against shareholder funds of Rs 90.49 lakhs, keeping the debt-to-equity ratio elevated near 2.8.
Mixed picture for shareholders — top-line shrank meaningfully but bottom-line improved on cost control, and reserves remain negative. The high debt relative to a small equity base keeps leverage risk in focus despite the profit recovery.